Diabetes research funding organisation JDRF has signed an industry development and discovery partnership with medical device start-up Cam Med to develop an insulin pump for artificial pancreas systems.
The funding provided by JDRF will be used to further develop and commercialise Cam Med’s thin and flexible, bandage-like patch pump called Evopump for automated insulin delivery.
Go deeper with GlobalData
Through the collaboration, JDRF aims to address the challenges with bulky automated insulin delivery systems by advancing the small-footprint Evopump, which is expected to provide improvement for paediatric and adult users.
JDRF Research programme scientist Jaime Giraldo said: “JDRF is excited to partner with Cam Med on improving insulin delivery hardware.
“The Evopump represents the type of miniaturised and user-centric design that could substantially reduce the burden of living with type 1 diabetes and remove obstacles preventing some people, particularly children, from using devices that could improve their glucose management.”
Evopump is designed as an automatically filled, actively controllable, wearable and disposable device to deliver one or more injectable drugs.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCam Med CTO Dr Zhifei Ge said: “The Evopump’s unique multi-reservoir, electrochemically actuated design is a game-changer not just in terms of its user-friendly, bandage-like form, but also because it enables the Evopump to be manufactured at a much lower cost than conventional pumps.”
Founded in 2014, the firm leverages microfluidics for the development of drug delivery technologies that facilitate substantial improvements in the daily lives of users.
